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Recently, we have found that a number of microRNAs (miRNAs) and proteins are involved in the response to acupuncture therapy
in hypertensive rats. Our bioinformatics study suggests an association between these miRNAs and proteins, which include miR-339
and sirtuin 2 (Sirt2). In this paper, we aimed to investigate whether Sirt2 was a direct target of miR-339 in neurons. In human SHSY5Y cells, the luciferase assay implied that Sirt2 was likely a target of miRNA-339. Overexpression of miR-339 downregulated Sirt2
expression, while knockdown of miR-339 upregulated Sirt2 expression in human SH-SY5Y cells and rat PC12 cells. In addition,
overexpression of miR-399 increased the acetylation of nuclear factor-𝜅B (NF-𝜅B) and forkhead box protein O1 (FOXO1) in SHSY5Y cells, which are known targets of Sirt2. Our findings demonstrate that miR-339 regulates Sirt2 in human and rat neurons.
Since Sirt2 plays a critical role in multiple important cellular functions, our data imply that acupuncture may act through epigenetic
changes and subsequent action on their targets, such as miRNA-339/Sirt2/NF-𝜅B/FOXO1 axis. Some physiological level changes
of neurons after altering the miR-339 levels are needed to validate the suggested therapeutic role of miR-339/Sirt2/NF-𝜅B/FOXO1
axis in response to acupuncture therapy in the future work.

1. Introduction
MicroRNAs (miRNAs) is a large family of endogenous,
small noncoding RNAs with 20–25 nucleotides that have
emerged as key posttranscriptional regulators of gene expression in mammals, bacteria, and plants [1–4]. The discovery
of miRNAs has revolutionized our comprehension of the
regulation of gene expression. Based on miRBase version
21 released in June 2014 (http://www.mirbase.org/), there
are 1,881 miRNA precursors and 2,588 mature miRNAs in
humans. miRNAs are predicted to control the activity of
more than 30% of human genes [5]. miRNAs are transcribed
as ∼70 nucleotide stem-loop precursors and subsequently

processed by the cytoplasmic RNase-III type enzyme Dicer
to generate ∼22 nucleotide mature products which can
target and modulate gene expression by inhibiting translation
and/or inducing degradation of target mRNAs [4, 6, 7]. The
mature miRNA is incorporated into a RNA-induced silencing
complex (RISC), which recognizes target mRNAs through
imperfect base pairing with the miRNA. miRNAs act as
adaptors that employ a silencing complex to target mRNAs
by selective base pairing, primarily in the 3 -untranslated
region (3 -UTR). Target interaction does not require perfect
complementarity between microRNA and mRNA sequences,
although near-perfect base pairing in a small region in the 5 end (positions 2–8) of the miRNA (sometimes termed “seed”)
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appears to be one of the key determinants of target recognition [4]. Gain and loss of function studies have indicated
that miRNAs play a critical role in the regulation of all key
biological functions such as development, cell proliferation,
cell differentiation, and apoptosis [3, 4]. miRNAs are also
associated with many human pathologies such as cancer,
heart diseases, diabetes, inflammatory diseases, autoimmune
diseases, and Alzheimer’s disease [1, 8–17].
Acupuncture is the stimulation of specific acupoints
along the skin of the body involving the application of
penetration of thin needles [18]. In the past 40 years, the
mechanistic studies of acupuncture mainly focus on (1) the
neural pathways involved in inflammation, pain, and cardiovascular effects [19–22]; (2) the involvement of the connective
tissues and their association with neural regulation [23, 24];
and (3) other molecular pathways that are involved in neural
response to acupuncture. In recent years, the application
of functional neuroimaging, microarray technology, proteomic analysis, and metabolomics analysis has significantly
improved our understanding of the mechanism of acupuncture [25–28]. However, although there are a large number of
mechanistic reports on the mechanism of acupuncture in the
literature, we still have a poor knowledge on how acupuncture
works [29].
Recent studies have revealed that a group of miRNAs
are involved in the neural mechanism of acupuncture treatment in hypertensive rats [30]. However, the targets of
acupuncture-regulated miRNAs are not fully identified and
validated and it is unknown whether this is involved in
acupuncture’s effects. In this study, we investigated if the
regulation of sirtuin 2 (Sirt2) was regulated by miR-339 in
human and rat neurons.

2. Materials and Methods
2.1. Bioinformatics Studies and Selection of Sirt2 as a Potential
Target of miR-339. Before starting the study, we performed
the microarray analysis to screen the miRNAs (including
miRNA-339) that responded to acupuncture therapy and
conducted the proteomic study to investigate the proteins
(including Sirt2) that responded to acupuncture therapy
in hypertensive rats [30, 31]. To check whether acupuncture therapy exerts its therapeutic effect through epigenetic
changes and subsequent action on their target, we conducted
a bioinformatics study to predict the miRNAs that could
regulate the genes that responded to acupuncture in hypertensive rats. MicroRNA.org (http://www.microrna.org/) was
applied to predict the miRNAs. From these predicted miRNAs, we choose the miRNAs which were consistent with
our previous study as candidate miRNAs for validation. The
bioinformatics study showed that seven miRNAs, including
miR-339, were predicted to regulate the human Sirt2 gene by
the microRNA.org program.
2.2. Cell Line and Cell Cultures. As previously described, rat
PC12 pheochromocytoma cells (ATCC, Manassas, VA, USA)
were grown in RPMI 1640 medium containing 10% fetal
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bovine serum (HyClone) and 5% horse serum (Invitrogen).
PC12 cells were induced to differentiate after 5-day treatment
with NGF by growing cells in low serum medium (RPMI 1640
medium with 1% horse serum) with 100 ng/mL NGF (R&D
Systems).
The human SH-SY5Y neuroblastoma cell line was provided (ATCC, Manassas, VA, USA). Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 2 mM L-glutamine, penicillin (20 units/mL), streptomycin (20 mg/mL), and 10% (vol/vol) heat-inactivated fetal
calf serum (Life Technologies). Cells were maintained at 37∘ C
in a saturated humidity atmosphere containing 95% air and
5% CO2 .
2.3. Generation of Sirt2 Construct and Luciferase Assays.
The Sirt2 3 -UTR target site was cloned into pMIR-reporter
luciferase vector (Invitrogen) using the following oligonucleotides (Integrated DNA Technologies Inc., Coralville,
Iowa, USA): sense, 5-CTAGTTTAACTCTTCCAGGACAGGGGGATCCA-3; and antisense, 5- AGCTTGGATCCCCCTGTCCTGGAAGAGTTAAA-3. We used a mutated
sequence by inserting the following oligonucleotides (Integrated DNA Technologies Inc.): sense, 5- CTAGTTTAACTCTTCCACGCCCGAGGGATCCA-3; and antisense, 5AGCTTGGATCCCTCGGGCGTGGAAGAGTTAAa-3.
SH-SY5Y cells were cultured in six-well plates at 1 ×
105 cells/well and transfected with different reporter vectors
(300 ng Luc-Empty, 300 ng Luc-Sirt2-3 -UTR, or 300 ng LucSirt2-3 -UTR-mut) and cotransfected with different concentration of miRNA-339 mimic (10 and 50 nM). Cells
were assayed 48 h after transfection with the dual-luciferase
reporter assay system (Invitrogen). Luciferase activity was
normalized by 𝛽-galactosidase activity.
2.4. Overexpression and Knockdown of miR-339 via Transfection. The nontargeting miRNA control, miR-339 mimic, and
miR-339 inhibitor were obtained from Invitrogen. Cells were
seeded in six-well plates at 1 × 105 cells/well and transfected
with different concentration of miRNA-339 mimic, miRNA339 inhibitor, or nontargeting miRNA control (10 and 50 nM)
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. Then, the cells were collected for
further analysis.
2.5. Western Blotting Assay. The cells were harvested and
lysed with the lysis buffer (50 mmol HEPES at pH 7.5,
150 mmol NaCl, 10% glycerol, 1.5 mmol MgCl2 , 1% TritonX 100, 1 mmol EDTA at pH 8.0, 10 mmol sodium pyrophosphate, 10 mmol sodium fluoride, and the protease inhibitor
cocktail) and centrifuged at 12,000 g for 15 min at 4∘ C.
Proteins in cell lysates (30 𝜇g/lane) were separated by 10%
SDS-PAGE, blotted, and detected with antibodies against
Sirt2 (1 : 1000; Cell Signaling Technology Inc.), acetyl-NF𝜅B
p65 (1 : 1000; Cell Signaling Technology Inc.), and acetylated
Foxo1 (AC-FKHR; 1 : 200; Santa Cruz Biotechnology, Inc.,
Texas, USA). Protein level was normalized to the matching
densitometric value of the internal control 𝛽-actin (1 : 1000,
Cell Signaling Technology Inc.).
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Figure 1: Sirt2 is regulated by miR-339 directly. (a) Sequence of
human miR-339 and the predicted binding sites with miR-339 within
Sirt2 untranslated region (3 -UTR) from different species are shown.
The sequence of Sirt2 3 -UTR mutant used for reporter assay is also
shown. (b) Luciferase reporter constructs containing 3 -UTR (LucSirt2-3 -UTR) or mutant 3 -UTR (Luc-Sirt2-3 -UTR-mut) of Sirt2
gene were cotransfected with miR-339 mimic or empty vector in
SH-SY5Y cell line and the luciferase activities were assayed (𝑛 = 6,
∗
𝑃 < 0.05 versus control).

2.6. Statistical Analysis. Data are presented as the mean ±
S.D. Multiple comparisons were evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s multiple
comparison procedure, with 𝑃 < 0.05 considered significant.
All statistical tests were performed using Prism software
version 6.0 (GraphPad Software Inc.).

3. Results
3.1. Luciferase Assay Implies That Sirt2 Is Likely a Direct Target
of miRNA-339 in SH-SY5Y Cells. To validate whether Sirt2
is a likely target of miR-339, we performed computational
miRNA target analysis, which showed that miRNA-339 was
able to bind to the Sirt2 mRNA 3 -UTR, suggesting this
gene might be a potential target for miRNA-339 (Figure 1(a)).
Moreover, to examine whether miR-339 could repress Sirt2
expression through direct 3 -UTR interaction, we cloned
Sirt2 3 -UTR luciferase reporter plasmid and performed
reporter analysis in SH-SY5Y cells. Our present data demonstrated that cotransfection of miR-339 mimic with Sirt2
3 -UTR reporter resulted in dose-dependent inhibition of
luciferase activity in SH-SY5Y cells (Figure 1(b), 𝑃 < 0.05

versus control). However, miR-339 failed to repress the
activity of Sirt2-3 -UTR reporter with a mutated miR-339
seed sequence (Figure 1(b)). These data indicated that Sirt2
was likely a direct target of miR-339.
3.2. Overexpression of miRNA-339 Downregulates Sirt2
Expression in Human SH-SY5Y Cells. To further validate
whether miRNA-339 could downregulate Sirt2 expression
in human neurons, we tested the effect of miRNA-339
on Sirt2 expression level in SH-SY5Y cells transfected
with miRNA-339 mimic. Overexpression of miRNA-339
significantly decreased Sirt2 expression in a dose-dependent
(Figure 2(a), 𝑃 < 0.01 versus control) and time-dependent
manner (Figure 2(b), 𝑃 < 0.05 versus control).
3.3. Overexpression of miRNA-339 Downregulates Sirt2
Expression in Rat PC12 Cells. To further validate whether
miRNA-339 can downregulate Sirt2 expression in rat
neurons, we tested the effect of miRNA-339 on Sirt2
expression level in NGF-induced PC12 cells transfected
with miRNA-339 mimic. Overexpression of miRNA-339
significantly decreased Sirt2 expression in a dose-dependent
(Figure 3(a), 𝑃 < 0.01 versus control) and time-dependent
manner (Figure 3(b), 𝑃 < 0.001 versus control).
3.4. Knockdown of miRNA-339 Upregulates Sirt2 Expression
in Rat PC12 Cells. To further validate whether knockdown of
miRNA-339 can upregulate Sirt2 expression in rat neurons,
we tested the effect of miRNA-339 on Sirt2 expression level
in NGF-induced PC12 cells transfected with miRNA-339
inhibitor. Knockdown of miRNA-339 significantly increased
Sirt2 expression in a dose-dependent (Figure 4(a), 𝑃 < 0.01
versus control) and time-dependent manner (Figure 4(b),
𝑃 < 0.001 versus control).
3.5. Overexpression of miRNA-339 Upregulates the Acetylated
NF-𝜅B and FOXO1 Expression Level in SH-SY5Y Cells. Our
results showed that Sirt2 is the direct target of miR-339, indicating that miR-339 can contribute to an upregulation of the
acetylated status of Sirt2 target, including NF-𝜅B and FOXO1.
To test this hypothesis, we measured the acetylated status of
Sirt2 target (NF-𝜅B and FOXO1) in SH-SY5Y cells treated
with miRNA-339 mimic. As we expected, overexpression of
miRNA-339 significantly increased the acetylation level of
NF-𝜅B and FOXO1 in a time-dependent manner (Figures 5(a)
and 5(b), 𝑃 < 0.01 versus control).

4. Discussion
In this paper, we firstly found that one of the acupunctureregulated targets, Sirt2, is likely a direct target of acupunctureregulated miRNA-339 in neurons. In addition, we demonstrated that altered Sirt2 expression by miR-339 activates its
targets such as NF-𝜅B and FOXO1 through increasing their
acetylation. Our findings implied that acupuncture may act
through epigenetic changes and subsequent action on their
targets, such as miRNA-339/Sirt2/NF-𝜅B/FOXO1 axis.
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Figure 2: Overexpression of miRNA-339 inhibited Sirt2 expression in human neurons. (a) Overexpression of miR-339 inhibited Sirt2
expression in a concentration-dependent manner. SH-SY5Y cells were treated with miRNA-339 mimic at 10 and 50 nM. Forty-eight hours
later, the cell lysates were collected for western blotting. 𝑁 = 6, ∗∗ 𝑃 < 0.01 versus control. (b) Overexpression of miR-339 inhibited Sirt2
expression in a time-dependent manner. SH-SY5Y cells were treated with miRNA-339 mimic at 50 nM for 24 and 48 h. At each time point,
the cell lysates were collected for western blotting. 𝑛 = 6, ∗ 𝑃 < 0.05 versus control.
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Figure 3: Overexpression of miRNA-339 also inhibited Sirt2 expression in rat neurons. (a) Overexpression of miR-339 inhibited Sirt2
expression in a concentration-dependent manner. NGF-induced differentiated PC12 cells were treated with miRNA-339 mimic at 10 and
50 nM. Forty-eight hours later, the cell lysates were collected for western blotting. 𝑛 = 6, ∗∗∗ 𝑃 < 0.001 versus control. (b) Overexpression
of miR-339 inhibited Sirt2 expression in a time-dependent manner. NGF-differentiated PC12 cells were treated with miRNA-339 mimic at
50 nM for 24 and 48 h. At each time point, the cell lysates were collected for western blotting. 𝑛 = 6, ∗∗∗ 𝑃 < 0.001 versus control.
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Figure 4: Knockdown of miRNA-339 increased Sirt2 expression in rat neurons. (a) Knockdown of miR-339 increased Sirt2 expression in
a concentration-dependent manner. NGF-induced differentiated PC12 cells were treated with miRNA-339 inhibitor at 10 and 50 nM. Fortyeight hours later, the cell lysates were collected for western blotting. 𝑛 = 6, ∗∗∗ 𝑃 < 0.001 versus control. (b) Knockdown of miR-339 increased
Sirt2 expression in a time-dependent manner. NGF-differentiated PC12 cells were treated with miRNA-339 inhibitor at 50 nM for 24 and 48 h.
At each time point, the cell lysates were collected for western blotting. 𝑛 = 6, ∗∗∗ 𝑃 < 0.001 versus control.
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Figure 5: MiRNA-339 increased the acetylated NF-𝜅B and FOXO1 expression level. Overexpression of miRNA-339 significantly increased
the acetylated NF-𝜅B (a) and FOXO1 (b) level in a time-dependent manner. SH-SY5Y cells were treated with miRNA-339 mimic at 50 nM for
24 and 48 h. At each time point, the cell lysates were collected for western blotting. 𝑛 = 6, ∗∗ 𝑃 < 0.01 versus control.
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Changes in miRNAs
(such as miR-339)

u
Changes in targets

(such as Sirt2)
AC-NF-𝜅B

AC-FOXO1

Therapeutic effects

Figure 6: Proposed mechanisms of the therapeutic effect of
acupuncture through epigenetic pathways. We propose that
acupuncture exerts its therapeutic effect through regulation of
miRNAs and its targets’ axis, such as miRNA-339/Sirt2/NF-𝜅B/
FOXO1 axis.

Sirt2 is one of the sirtuin family (SIRT1–7), which is
known to be most predominantly expressed in the brain.
Sirtuins are a class of proteins that possess deacylase activity,
including deacetylase activity [32–36]. Sirtuins have been

implicated as a regulator of a variety of important biological
process, like aging, metabolism, and stress resistance [34].
Our previous study and other studies have showed that
acupuncture can exert its therapeutic effect involved with
regulating sirtuin expression (including Sirt1 and Sirt2) [31,
35, 37]. Our present data showed that Sirt2 is likely a direct
target of miRNA-339, which leads to a better explanation as to
why acupuncture upregulated miRNA-339 expression companion with acupuncture downregulation of Sirt2 expression
in hypertensive rats. There are three transcript isoforms of
Sirt2 gene, including isoform 1 (43 kD), isoform 2 (39 kD),
and isoform 5, but only 43 kD Sirt2 was affected after miR339 overexpression or knockdown according to our present
data. One of the possible explanations is that the human Sirt2
mRNA has an open reading frame of 1,167 bp that encodes
two isoforms of the Sirt2 protein: isoform 1 encodes a 389aa protein with a predictive molecular weight of 43.2 kD,
while isoform 2, which is lacking the first three exons,
encodes a 352-aa protein with a predictive molecular weight
of 39.5 kD. Our data also showed that miR-339 increased the
acetylated NF-𝜅B and FOXO1 expression level. NF-𝜅B and
FOXO1 are targets of Sirt2. Decreased expression level of Sirt2
activates NF-𝜅B and FOXO1 by increasing its acetylation. This
could lead to exerting acupuncture therapeutic effect. Further
studies are needed to validate whether miR-339 increased the
acetylated NF𝜅B and FOXO1 by regulating the protein levels,
stability, or activity of Sirt2.
Taken together, we proposed that acupuncture exerts its
therapeutic effects through a series of biological processes
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including (Figure 6) (1) changes of miRNAs (such as miR339); (2) changes of targets (such as Sirt2); and (3) altered
expression levels of Sirt2 activating its targets such as NF𝜅B
and FOXO1. These events will result in remarkable therapeutic effects observed in vivo.
A possible limitation of the present study was that some
physiological level changes of neurons after altering the miR339 levels are needed to validate the proposed therapeutic role
of miR-339/Sirt2/NF𝜅B/FOXO1 axis in response to acupuncture therapy in the future work.
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